Literature DB >> 17138506

Addressing the issue of channeling bias in observational studies with propensity scores analysis.

Francis S Lobo1, Samuel Wagner, Cynthia R Gross, Jon C Schommer.   

Abstract

Randomized Clinical Trials (RCTs) remain the gold standard for determining the utility of pharmaceuticals especially from a safety and efficacy standpoint. However, restrictive entry criteria and stringent protocols can be barriers to generalizing RCT findings to real world practices and outcomes. Observational studies overcome these limitations of RCTs since they are representative of real world populations and practices. Nonetheless, attributing causality remains a major limitation in observational studies, due to the non-random assignment of subjects to treatment. Non-random assignment can lead to imbalances in risk-factors between the groups being compared and thus bias the estimates of the treatment effect. Non-random assignment can be particularly problematic in observational studies comparing older versus newer pharmaceuticals from similar therapeutic classes due to the phenomenon of channeling. Channeling occurs when drug therapies with similar indications are preferentially prescribed to groups of patients with varying baseline prognoses. In this manuscript we discuss the phenomenon of channeling and the use of a statistical technique known an propensity scores analysis which potentially adjusts for the effects of channeling. During the course of this manuscript we discuss tests for determining the quality of the derived propensity score, various techniques for utilizing propensity scores, and also the potential limitations of this technique. With the increasing availability of high quality pharmaceutical and medical claims data for use in observational studies, increased attention must be given to analytic techniques that adjust optimally for non-random assignment and resulting channeling bias. For research studies using observational study designs, propensity score analysis offers a reasonable solution to address the limitation of non-random assignment, especially when RCTs are too costly, time-consuming or not ethically feasible.

Entities:  

Mesh:

Year:  2006        PMID: 17138506     DOI: 10.1016/j.sapharm.2005.12.001

Source DB:  PubMed          Journal:  Res Social Adm Pharm        ISSN: 1551-7411


  25 in total

1.  Better survival of right-sided than left-sided stage II colon cancer: a propensity scores matching analysis based on SEER database.

Authors:  Shuanhu Wang; Xinxin Xu; Jiajia Guan; Rui Huo; Mulin Liu; Congqiao Jiang; Wenbin Wang
Journal:  Turk J Gastroenterol       Date:  2020-11       Impact factor: 1.852

2.  The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database.

Authors:  Ryoko Sakai; Soo-Kyung Cho; Toshihiro Nanki; Ryuji Koike; Kaori Watanabe; Hayato Yamazaki; Hayato Nagasawa; Koichi Amano; Yoshiya Tanaka; Takayuki Sumida; Atsushi Ihata; Shinsuke Yasuda; Atsuo Nakajima; Takahiko Sugihara; Naoto Tamura; Takao Fujii; Hiroaki Dobashi; Yasushi Miura; Nobuyuki Miyasaka; Masayoshi Harigai
Journal:  Rheumatol Int       Date:  2014-05-23       Impact factor: 2.631

3.  Evaluation of the Case-Crossover (CCO) Study Design for Adverse Drug Event Detection.

Authors:  Zachary Burningham; Tao He; Chia-Chen Teng; Xi Zhou; Jonathan Nebeker; Brian C Sauer
Journal:  Drug Saf       Date:  2017-09       Impact factor: 5.606

4.  Myelosuppression with Oxazolidinones: Are There Differences?

Authors:  Cathy Hardalo; Thomas P Lodise; Carisa De Anda
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

5.  A Prospective Cohort Study of the Impact of Return-to-Work Coordinators in Getting Injured Workers Back on the Job.

Authors:  Tyler J Lane; Rebbecca Lilley; Sheilah Hogg-Johnson; Anthony D LaMontagne; Malcolm R Sim; Peter M Smith
Journal:  J Occup Rehabil       Date:  2018-06

Review 6.  Prescribing proton pump inhibitors: is it time to pause and rethink?

Authors:  Nimish Vakil
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

Review 7.  Osteoporosis therapies: evidence from health-care databases and observational population studies.

Authors:  Stuart L Silverman
Journal:  Calcif Tissue Int       Date:  2010-08-20       Impact factor: 4.333

8.  In vitro fertilisation with recombinant follicle stimulating hormone requires less IU usage compared with highly purified human menopausal gonadotrophin: results from a European retrospective observational chart review.

Authors:  Geoffrey H Trew; Adam P Brown; Samantha Gillard; Stuart Blackmore; Christine Clewlow; Paul O'Donohoe; Radoslaw Wasiak
Journal:  Reprod Biol Endocrinol       Date:  2010-11-08       Impact factor: 5.211

9.  Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study.

Authors:  Daniel A Barocas; Vivien Chen; Matthew Cooperberg; Michael Goodman; John J Graff; Sheldon Greenfield; Ann Hamilton; Karen Hoffman; Sherrie Kaplan; Tatsuki Koyama; Alicia Morgans; Lisa E Paddock; Sharon Phillips; Matthew J Resnick; Antoinette Stroup; Xiao-Cheng Wu; David F Penson
Journal:  J Comp Eff Res       Date:  2013-07       Impact factor: 1.744

10.  A Systematic Review and Meta-Analyses of the Association Between Anti-Hypertensive Classes and the Risk of Falls Among Older Adults.

Authors:  Hui Ting Ang; Ka Keat Lim; Yu Heng Kwan; Pui San Tan; Kai Zhen Yap; Zafirah Banu; Chuen Seng Tan; Warren Fong; Julian Thumboo; Truls Ostbye; Lian Leng Low
Journal:  Drugs Aging       Date:  2018-07       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.